Natco Gets US FDA Nod for API Unit

  Published 1 year ago

Natco Pharma received a US FDA EIR for its Mekaguda API unit after a June inspection with a single VAI observation.

  • Inspection occurred from June 9–13, 2025; only one observation was noted, categorized as voluntary action indicated (VAI).
  • Regulatory filing confirms receipt of Establishment Inspection Report (EIR), indicating closure of inspection process.
  • Natco develops APIs, generics, specialty drugs, and crop protection products from its Hyderabad-based headquarters.

You might like these

Kaynes Tech India Invests $1.03M in Parent Company Shares

MCX Fined for Platform Disclosure Lapses

India's Markets Tumble Amid Mideast Tensions, Air Crash

MRPL Reports Q1 Loss, Revenue Drops

Wipro Jumps 4% on Strong Q1

Markets Slip as RBI Holds Rates Steady

Schneider to Fully Own India JV

News that matters the most ⚡